Genetic Disease Screening Program, California Department of Public Health, Richmond, and the Division of Maternal Fetal Medicine, University of California, San Francisco, and the Department of Epidemiology and Biostatistics, University of California San Francisco School of Medicine, San Francisco, California; and the Division of Maternal Fetal Medicine, University of Hawaii, Honolulu, Hawaii.
Obstet Gynecol. 2014 Mar;123(3):603-609. doi: 10.1097/AOG.0000000000000145.
To assess the risk of adverse obstetric, perinatal, and fetal outcomes for pregnant women participating in prenatal sequential integrated screening through the California Prenatal Screening Program who had a false-positive screening result.
Women who underwent first- and second-trimester prenatal integrated screening plus nuchal translucency measurement with outcome information available were included. Fetuses and neonates with chromosomal or neural tube defects were excluded. We compared the risk of adverse outcomes for all women with a positive screening result compared with a 10% random sample of women with a negative screening result. Logistic binomial regression was used to compare adverse outcomes in screen-positive compared with screen-negative women.
We identified 9,051 screen-positive and 30,928 screen-negative pregnancies with outcome information available. Compared with screen-negative pregnancies, screen-positive women were more likely to be diagnosed with preeclampsia, placenta previa, or abruption (7.6% screen-positive, 3.8% screen-negative; relative risk 1.7, 95% confidence interval [CI] 1.6-1.8) or experience fetal loss before 20 weeks of gestation (1.9% screen-positive, 0.2% screen-negative; relative risk 3.5, 95% CI 3.2-3.8). Women with positive results for more than one screened condition were at substantially greater risk of fetal and neonatal mortality (relative risks 33.6-156.7, 95% CIs 21.8-194.4).
Among pregnancies without chromosomal or neural tube defects, prenatal sequential integrated screening provides information regarding risk across a variety of adverse pregnancy outcomes.
评估参加加利福尼亚产前筛查计划的孕妇中,产前连续综合筛查结果阳性者的不良产科、围产儿和胎儿结局风险。
纳入接受过第一和第二孕期产前综合筛查加颈项透明层测量且有结局信息的孕妇。排除有染色体或神经管缺陷的胎儿和新生儿。我们比较了所有筛查阳性者与 10%随机筛查阴性者的不良结局风险。采用逻辑二项式回归比较了筛查阳性者与筛查阴性者的不良结局。
我们确定了 9051 例筛查阳性和 30928 例筛查阴性且有结局信息的妊娠。与筛查阴性妊娠相比,筛查阳性者更有可能被诊断为子痫前期、前置胎盘或胎盘早剥(7.6%筛查阳性,3.8%筛查阴性;相对风险 1.7,95%置信区间[CI]1.6-1.8)或在 20 周妊娠前发生胎儿丢失(1.9%筛查阳性,0.2%筛查阴性;相对风险 3.5,95%CI 3.2-3.8)。有多种筛查阳性结果的女性发生胎儿和新生儿死亡的风险显著增加(相对风险 33.6-156.7,95%CI 21.8-194.4)。
在无染色体或神经管缺陷的妊娠中,产前连续综合筛查可提供多种不良妊娠结局风险的信息。